大博医疗
(002901)
| 流通市值：109.85亿 | | | 总市值：129.71亿 |
| 流通股本：3.51亿 | | | 总股本：4.14亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,533,121,281.8 | 1,125,437,608.63 | 749,642,994.54 | 391,374,553 |
| 营业收入 | 1,533,121,281.8 | 1,125,437,608.63 | 749,642,994.54 | 391,374,553 |
| 二、营业总成本 | 1,459,172,978.12 | 1,046,739,500.28 | 669,831,385.06 | 330,218,836.15 |
| 营业成本 | 492,239,429.55 | 368,265,693.97 | 227,304,362.15 | 118,575,146.96 |
| 税金及附加 | 14,361,576.58 | 9,431,343.69 | 6,712,897.72 | 2,078,603.69 |
| 销售费用 | 564,964,583.13 | 409,070,667.67 | 271,474,881.93 | 128,253,971.59 |
| 管理费用 | 125,518,339.26 | 86,239,506.18 | 56,310,955.05 | 25,771,956.77 |
| 研发费用 | 285,275,500.97 | 191,799,717.78 | 125,550,165.56 | 63,032,915.87 |
| 财务费用 | -23,186,451.37 | -18,067,429.01 | -17,521,877.35 | -7,493,758.73 |
| 其中:利息费用 | 7,158,603.61 | 3,688,061.51 | 1,488,882.83 | 296,967.63 |
| 其中:利息收入 | 29,905,982.49 | 21,510,244.43 | 13,428,890.67 | 8,564,374.1 |
| 加:公允价值变动收益 | 5,601,864.97 | 112,784.67 | 321,122.22 | -1,192,489.91 |
| 加:投资收益 | 9,746,765.11 | 6,606,030.21 | 3,779,096.95 | 3,404,961.85 |
| 资产处置收益 | 302,702.99 | 178,546.68 | 173,882.78 | 171,020.96 |
| 资产减值损失(新) | -50,141,494.2 | -4,635,184.78 | -5,277,322.6 | -7,268,516.65 |
| 信用减值损失(新) | 922,211.89 | 5,776,603.84 | 129,193.15 | -1,007,191.53 |
| 其他收益 | 62,855,864.84 | 48,849,634.73 | 29,479,785.83 | 10,708,423.98 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 103,236,219.28 | 135,586,523.7 | 108,417,367.81 | 65,971,925.55 |
| 加:营业外收入 | 218,780.24 | 115,265.27 | 48,978.09 | 227,697.53 |
| 减:营业外支出 | 3,714,158.51 | 5,413,412.15 | 751,676.97 | 262,040.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 99,740,841.01 | 130,288,376.82 | 107,714,668.93 | 65,937,582.8 |
| 减:所得税费用 | 13,404,821.8 | 12,818,882.22 | 6,010,371.3 | 3,192,432.31 |
| 六、净利润 | 86,336,019.21 | 117,469,494.6 | 101,704,297.63 | 62,745,150.49 |
| 持续经营净利润 | 86,336,019.21 | 117,469,494.6 | 101,704,297.63 | 62,745,150.49 |
| 归属于母公司股东的净利润 | 58,972,461.01 | 97,715,980.67 | 93,535,390.85 | 58,209,336.93 |
| 少数股东损益 | 27,363,558.2 | 19,753,513.93 | 8,168,906.78 | 4,535,813.56 |
| (一)基本每股收益 | 0.14 | 0.24 | 0.23 | 0.14 |
| (二)稀释每股收益 | 0.14 | 0.24 | 0.23 | 0.14 |
| 八、其他综合收益 | -196,716.25 | 550,122.39 | 926,220.34 | 517,084.22 |
| 归属于母公司股东的其他综合收益 | -197,884.59 | 281,451.08 | 643,544.47 | 517,084.22 |
| 九、综合收益总额 | 86,139,302.96 | 118,019,616.99 | 102,630,517.97 | 63,262,234.71 |
| 归属于母公司股东的综合收益总额 | 58,774,576.42 | 97,997,431.75 | 94,178,935.32 | 58,726,421.15 |
| 归属于少数股东的综合收益总额 | 27,364,726.54 | 20,022,185.24 | 8,451,582.65 | 4,535,813.56 |
| 公告日期 | 2024-03-30 | 2023-10-27 | 2023-08-31 | 2023-04-29 |
| 审计意见(境内) | 标准无保留意见 | | | |